Human Nonalcoholic Steatohepatitis on a Chip

May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, Ermanno Gherardi, Shiladitya Sengupta, Hae Lin Jang – 29 November 2020 – Nonalcoholic steatohepatitis (NASH), an advanced stage of nonalcoholic fatty liver disease (NAFLD), is a rapidly growing and global health problem compounded by the current absence of specific treatments. A major limiting factor in the development of new NASH therapies is the absence of models that capture the unique cellular structure of the liver microenvironment and recapitulate the complexities of NAFLD progression to NASH.

A Prospective Study of the Prevalence of Parkinsonism in Patients With Liver Cirrhosis

Diana Apetauerova, Peter Hildebrand, Stephanie Scala, Janet W. Zani, LeeAnne Lipert, Erin Clark, Tanya Fennell, Fredric D. Gordon – 26 November 2020 – Acquired hepatocerebral degeneration refers to a neurological syndrome consisting of various movement disorders and cognitive impairment in advanced liver cirrhosis or portosystemic shunt. Neurological signs and symptoms may be attributed to the accumulation of toxic substances in the brain. The most common neurological presentation of this is parkinsonism.

Protein Phosphatase 1 Regulatory Subunit 3B Genotype at rs4240624 Has a Major Effect on Gallbladder Bile Composition

Ville Männistö, Dorota Kaminska, Pirjo Käkelä, Mikko Neuvonen, Mikko Niemi, Marcus Alvarez, Päivi Pajukanta, Stefano Romeo, Max Nieuwdorp, Albert.K. Groen, Jussi Pihlajamäki – 25 November 2020 – The protein phosphatase 1 regulatory subunit 3B (PPP1R3B) gene is a target of farnesoid X receptor (FXR), which is a major regulator of bile acid metabolism. Both PPP1R3B and FXR have been suggested to take part in glycogen metabolism, which may explain the association of PPP1R3B gene variants with altered hepatic computed tomography attenuation.

Hypothermic Oxygenated Perfusion Improves Extended Criteria Donor Liver Graft Function and Reduces Duration of Hospitalization Without Extra Cost: The PERPHO Study

Michel Rayar, Jean‐Marie Beaurepaire, Emma Bajeux, Stéphanie Hamonic, Thomas Renard, Clara Locher, Véronique Desfourneaux, Aude Merdrignac, Damien Bergeat, Mohamed Lakehal, Laurent Sulpice, Pauline Houssel‐Debry, Caroline Jezequel, Christophe Camus, Edouard Bardou‐Jacquet, Bernard Meunier – 25 November 2020 – Few studies have evaluated the efficacy or the cost of hypothermic oxygenated perfusion (HOPE) in the conservation of extended criteria donor (ECD) grafts from donation after brain death (DBD) donors during liver transplantation (LT).

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma

Kyohei Yugawa, Shinji Itoh, Tomoharu Yoshizumi, Norifumi Iseda, Takahiro Tomiyama, Akinari Morinaga, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Yoshinao Oda, Masaki Mori – 24 November 2020 – CKLF‐like MARVEL transmembrane domain containing 6 (CMTM6) was identified as a regulator of programmed death ligand 1 (PD‐L1), which induces antitumor immunity in several cancers. This study aimed to clarify the relationship between CMTM6 and PD‐L1 expression and clinical outcomes in patients with hepatocellular carcinoma (HCC).

Subscribe to